NASDAQ: DMAC - DiaMedica Therapeutics Inc.

半年間の収益性: -8.83%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール DiaMedica Therapeutics Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.

さらに詳しく
The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2008-01-04
ISIN CA25253X2077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.diamedica.com
Цена ао 4.08
1日あたりの価格変動: -7.73% (4.14)
週ごとの価格変動: -23.29% (4.98)
月ごとの料金変更: -38.88% (6.25)
3ヶ月間の価格変動: -29.39% (5.41)
半年間の価格変動: -8.83% (4.19)
年間の価格変動: +37.91% (2.77)
3年間の価格推移: +36.43% (2.8)
5年間の価格推移: -15.49% (4.52)
年初からの価格変動: -29.65% (5.43)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 1.82 8
P/E 0 0
EV/EBITDA -4.18 0
合計: 3.5

効率

名前 意味 学年
ROA, % -35.78 0
ROE, % -37.96 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0188 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 1375.75 10
収益性 Ebitda, % 80.45 9
収益性 EPS, % -33 0
合計: 7.6
さらに詳しく

機関 音量 共有, %
Cooperman, Leon G. 883623 2.33
Vanguard Group Inc 802171 2.11
Paragon Associates & Paragon Associates Ii Joint Venture 500000 1.32
Altium Capital Management, LP 287698 0.76
Bleichroeder LP 222317 0.59
Geode Capital Management, LLC 218778 0.58
Jacob Asset Management Of New York LLC 168730 0.44
Northern Trust Corporation 133633 0.35
Morgan Stanley 120995 0.32
First Manhattan Company 114744 0.3

ETF共有, %年間の利益率, %配当金, %
iShares Micro-Cap ETF 0.02526 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.00098 27.77 1.68271
0.0122.431.61



スーパーバイザー 役職 支払い 生年
Mr. Dietrich John Pauls MBA President, CEO & Director 818.61k 1971 (54 年)
Mr. Scott Kellen CPA CFO & Corporate Secretary 485.43k 1965 (60 年)
Dr. Ambarish Shah Ph.D. Chief Technology Officer N/A
Mr. Dominic R. Cundari Chief Commercial Officer N/A 1951 (74 年)
Mr. David J. Wambeke Chief Business Officer N/A 1984 (41 年)
Dr. Lorianne K. Masuoka M.D. Chief Medical Officer N/A 1961 (64 年)

住所: United States, Minneapolis. MN, 301 Carlson Parkway - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.diamedica.com